Weekly injection for teens with achondroplasia
Part of Bones, joints & muscles, Genetic & congenital clinical trials.
This trial tests a weekly injection called navepegritide for adolescents aged 12-18 with achondroplasia (a common form of dwarfism). The goal is to see if it can safely improve growth. You must have a genetic confirmation of achondroplasia and a historical height measurement from the past 6 to 15 months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 12 and 17 years old (inclusive).
- You have achondroplasia confirmed by a genetic test (a past test result is okay).
- You have at least one height measurement from your medical records taken 6 to 15 months ago.
- A parent or guardian is willing to give you a weekly injection under the skin at home.
- You have not had any surgery or medication intended to increase your height (like growth hormone or leg-lengthening surgery).
- You do not have other conditions that cause short stature (like growth hormone deficiency, Turner syndrome, or celiac disease).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new weekly injection called TransCon CNP for infants with achondroplasia (the most common form of dwarfism). The goal is to see if it can help children grow better than a placebo (a shot with no medicine).
This trial looks at how safe and effective weekly under-the-skin (subcutaneous) TransCon CNP is for children and teens with achondroplasia over the long term. You may be considered if your child has already finished a previous TransCon CNP study and can follow weekly injection and follow-up visits.
This trial tests a new medicine for children with achondroplasia (a common form of dwarfism). It aims to see if the drug can improve growth. The study is for children aged 2.5 to under 11 years old who have not started puberty and can walk without help.
This trial tests a new medicine (ABSK061) for children with achondroplasia, a common form of dwarfism. It aims to see if the drug is safe and can help with growth. Children age 3 to under 12 may qualify.
This trial tests a new medicine, BMN 333, against an existing one (vosoritide) to see if it helps children with achondroplasia grow. It's for kids who haven't used these treatments before.
This trial tests a new medicine (KK8398) for children with achondroplasia (a common cause of dwarfism). It aims to see if the medicine can help improve bone growth and safety. It may be a good option for children who haven't yet reached their final height and haven't been treated with other growth therapies.
Hear when a new Achondroplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.